Lisa Neuman

Studies offer hope that CGRP antibodies will lead to better treatment for disabling headaches.

Positive 5-year efficacy and safety results shown for the interleukin-17A inhibitor.

The FDA expanded approval of a self-expanding TAVR platform to include patients who are at an intermediate risk for open-heart surgery.

The EMPA-REG OUTCOME trial shows short- and long-term benefits of empagliflozin on albuminuria in patients with T2D and CVD.

A small number of NovoPen Echo devices may crack or break if exposed to certain chemicals.

The drug reduced risk of overall symptomatic hypoglycemia compared to insulin glargine U100.

Two therapies showed positive effect in less than 4 hours for treatment of children and adolescents with PTSD.

A meta-analysis provides no support for theory that incretin-based treatment causes increased mortality in patients with T2D.

Eptinezumab for frequent episodic migraine (EM) met primary and key secondary endpoints in the PROMISE 1 phase 3 trial.

An investigational form of buprenorphine has been found to meet its primary and secondary endpoints in a phase 3 trial.

Certain microbial strains persisted in donor recipients for as long as 2 years after an FMT.

An epidemiologist shares his knowledge about Clostridium difficile prevention and control.

Access to a transition coordinator benefited youths with T1D during their transition period.

Maternal use of lithium in the first trimester raises risk of cardiac defects to the fetus.

Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.

Human antibody may substantially reduce need for insulin in patients with T1D.

Results have major worldwide implications for type 2 diabetes treatment.

New-generation insulin found to have comparable cardiovascular safety to insulin glargine and significantly reduce episodes of severe hypoglycemia.

Two pivotal studies on sotagliflozin were presented at the ADA’s 77th Scientific Sessions.

Insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL combined lowered A1C levels by 1.09% to 2.41% after 30 weeks.

Metformin may reduce the risk of heart disease in adults with T1D.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

ODYSSEY DM-INSULIN is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Merck and Pfizer have announced that VERTIS MET and VERTIS SITA met primary endpoints.

Patients who switched to insulin glargine 300 Units/mL were 57% less likely to experience hypoglycemia at 6-months.

Teens with T1D improved their A1C levels by frequent 2-way texting.

Severely obese American Indian children had a 12-times higher risk of developing T2D as normal-weight youth.

Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.

More than 3,000 original research presentations will be offered in a robust 5-day program.

Associations between race/ethnicity and lack of in healthcare access were found.